138 related articles for article (PubMed ID: 36594511)
1. A simple mathematical model of cyclic hypoxia and its impact on hypofractionated radiotherapy.
Taylor E
Med Phys; 2023 Mar; 50(3):1893-1904. PubMed ID: 36594511
[TBL] [Abstract][Full Text] [Related]
2. Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.
Lindblom E; Dasu A; Toma-Dasu I
Acta Oncol; 2015; 54(9):1592-8. PubMed ID: 26217986
[TBL] [Abstract][Full Text] [Related]
3. Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation.
Chvetsov AV; Rajendran JG; Zeng J; Patel SA; Bowen SR; Kim EY
Med Phys; 2017 May; 44(5):1975-1982. PubMed ID: 28236652
[TBL] [Abstract][Full Text] [Related]
4. A radiobiological model of reoxygenation and fractionation effects.
Guerrero M; Carlson DJ
Med Phys; 2017 May; 44(5):2002-2010. PubMed ID: 28273349
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia.
Ruggieri R
Phys Med Biol; 2004 Oct; 49(20):4811-23. PubMed ID: 15566177
[TBL] [Abstract][Full Text] [Related]
6. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
[TBL] [Abstract][Full Text] [Related]
7. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
[TBL] [Abstract][Full Text] [Related]
8. Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes.
Chvetsov AV; Hanin LG; Stewart RD; Zeng J; Rengan R; Lo SS
Phys Med Biol; 2021 Jun; 66(12):. PubMed ID: 34030139
[TBL] [Abstract][Full Text] [Related]
9. Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.
Lindblom E; Antonovic L; Dasu A; Lax I; Wersäll P; Toma-Dasu I
Radiat Oncol; 2014 Jun; 9():149. PubMed ID: 24974778
[TBL] [Abstract][Full Text] [Related]
10. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
[TBL] [Abstract][Full Text] [Related]
11. Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling.
Ruggieri R; Stavreva N; Naccarato S; Stavrev P
Phys Med Biol; 2013 Jul; 58(13):4611-20. PubMed ID: 23771131
[TBL] [Abstract][Full Text] [Related]
12. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
Shibamoto Y; Miyakawa A; Otsuka S; Iwata H
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i76-i82. PubMed ID: 27006380
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Radiobiological Advantages of Hypofractionation Compared with Conventional Fractionation: Early-Passage NSCLC Cells are Less Aggressive after Hypofractionation.
Zhang H; Wan C; Huang J; Yang C; Qin Y; Lu Y; Ma J; Wu B; Xu S; Wu G; Yang K
Radiat Res; 2018 Dec; 190(6):584-595. PubMed ID: 30234458
[TBL] [Abstract][Full Text] [Related]
14. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
15. Effect of reoxygenation on hypofractionated radiotherapy of prostate cancer.
Kuperman VY; Lubich LM
Med Phys; 2020 Oct; 47(10):5383-5391. PubMed ID: 32583529
[TBL] [Abstract][Full Text] [Related]
16. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
17. "Primer shot" fractionation with an early treatment break is theoretically superior to consecutive weekday fractionation schemes for early-stage non-small cell lung cancer.
Gouw ZAR; Jeong J; Rimner A; Lee NY; Jackson A; Fu A; Sonke JJ; Deasy JO
Radiother Oncol; 2024 Jan; 190():110006. PubMed ID: 37972733
[TBL] [Abstract][Full Text] [Related]
18. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
[TBL] [Abstract][Full Text] [Related]
19. A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: analysis of data from the literature.
Kong C; Guo WJ; Zha WW; Zhu XZ; Huang SF; Zhang YW; Xu JH; He X
Lung Cancer; 2014 Apr; 84(1):7-12. PubMed ID: 24548340
[TBL] [Abstract][Full Text] [Related]
20. Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.
Ohri N; Dicker AP; Lawrence YR
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):385-93. PubMed ID: 22265460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
